Literature DB >> 11060312

A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

B I Giasson1, I V Murray, J Q Trojanowski, V M Lee.   

Abstract

Neuronal and oligodendrocytic aggregates of fibrillar alpha-synuclein define several diseases of the nervous system. It is likely that these inclusions impair vital metabolic processes and compromise viability of affected cells. Here, we report that a 12-amino acid stretch ((71)VTGVTAVAQKTV(82)) in the middle of the hydrophobic domain of human alpha-synuclein is necessary and sufficient for its fibrillization based on the following observations: 1) human beta-synuclein is highly homologous to alpha-synuclein but lacks these 12 residues, and it does not assemble into filaments in vitro; 2) the rate of alpha-synuclein polymerization in vitro decreases after the introduction of a single charged amino acid within these 12 residues, and a deletion within this region abrogates assembly; 3) this stretch of 12 amino acids appears to form the core of alpha-synuclein filaments, because it is resistant to proteolytic digestion in alpha-synuclein filaments; and 4) synthetic peptides corresponding to this 12-amino acid stretch self-polymerize to form filaments, and these peptides promote fibrillization of full-length human alpha-synuclein in vitro. Thus, we have identified key sequence elements necessary for the assembly of human alpha-synuclein into filaments, and these elements may be exploited as targets for the design of drugs that inhibit alpha-synuclein fibrillization and might arrest disease progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11060312     DOI: 10.1074/jbc.M008919200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  335 in total

1.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  De novo designed peptide-based amyloid fibrils.

Authors:  Manuela López De La Paz; Kenneth Goldie; Jesús Zurdo; Emmanuel Lacroix; Christopher M Dobson; Andreas Hoenger; Luis Serrano
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-27       Impact factor: 11.205

3.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 4.  Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.

Authors:  Nicole Exner; Anne Kathrin Lutz; Christian Haass; Konstanze F Winklhofer
Journal:  EMBO J       Date:  2012-06-26       Impact factor: 11.598

5.  Many overlapping peptides for protein hydrogen exchange experiments by the fragment separation-mass spectrometry method.

Authors:  Leland Mayne; Zhong-Yuan Kan; Palaniappan Sevugan Chetty; Alec Ricciuti; Benjamin T Walters; S Walter Englander
Journal:  J Am Soc Mass Spectrom       Date:  2011-09-14       Impact factor: 3.109

6.  Exosomes-associated neurodegeneration and progression of Parkinson's disease.

Authors:  Isabella Russo; Luigi Bubacco; Elisa Greggio
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

7.  Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein.

Authors:  Robert Bussell; Trudy Fiona Ramlall; David Eliezer
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

8.  Adsorption and decontamination of α-synuclein from medically and environmentally-relevant surfaces.

Authors:  Hanh T M Phan; Jason C Bartz; Jacob Ayers; Benoit I Giasson; Mathias Schubert; Keith B Rodenhausen; Negin Kananizadeh; Yusong Li; Shannon L Bartelt-Hunt
Journal:  Colloids Surf B Biointerfaces       Date:  2018-03-09       Impact factor: 5.268

Review 9.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 10.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.